What type of study is this?

December 8, 2025BloodOpen Access

Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows low-dose rituximab achieves 92% EBV clearance in patients, suggesting a safer option than high-dose regimens.

High EBV clearance rate of 92% achieved with low-dose rituximab, minimizing toxicity risk.
Among 77 patients, 70 successfully cleared EBV, indicating effective preemptive treatment following transplant.
Retrospective analysis of patients receiving low-dose rituximab for viral load after allogeneic hematopoietic stem cell transplantation.
Low-dose regimens may enhance patient safety by reducing immunosuppression and adverse events post-transplant.

Yi Wang (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows low-dose rituximab achieves 92% EBV clearance in patients, suggesting a safer option than high-dose regimens.